Dental implant

Search documents
中国医疗保健_ 银发的崛起-China Healthcare_ The Rise of the Silver Yuan
2025-07-29 02:31
EQUITY RESEARCH | 28 July 2025 | 4:22PM CST China Healthcare The Rise of the Silver Yuan While key debates have recently centered around the impact from volume based procurement (VBP) on overall healthcare (HC) spending, we highlight an increasingly important demographic — the 'silver' population (aged 50 and above) with strong 'Yuan' spending power (>Rmb3mn net worth). With this report, we introduce standalone TAM estimates for this '50+ >Rmb3mn NW' cohort, growing from Rmb221bn (US$31bn) to Rmb963bn (US$1 ...
ZimVie to Report Second Quarter 2025 Financial Results on July 30, 2025
Globenewswire· 2025-07-25 12:00
PALM BEACH GARDENS, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced it will report financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q after market close on Wednesday, July 30, 2025. On July 21, 2025, ZimVie issued a press release announcing ZimVie’s entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED (“ARCHIMED”) for $19.00 ...
ZimVie Announces Exclusive Distribution Agreement with Osstem Implant to Expand Premium Dental Implant Offering in China
Globenewswire· 2025-07-23 20:05
Core Insights - ZimVie Inc. has entered a strategic distribution agreement with Osstem Implant Co., Ltd. to enhance its presence in the growing Chinese dental implant market, which is estimated to exceed 10 million units annually [1][2] Company Overview - ZimVie is a global leader in the dental implant market, focusing on developing and delivering a comprehensive portfolio of products for dental tooth replacement and restoration [5] - Osstem Implant, founded in 1997, is the largest dental implant manufacturer globally and a leading provider in the Asia-Pacific region, with a strong distribution network in over 90 countries [6] Market Dynamics - The partnership allows ZimVie to leverage Osstem's established distribution channels and clinical training programs, enhancing customer access to ZimVie's innovative implant portfolio [2][4] - Osstem Implant has built a robust presence in over 90 cities in China and conducts nearly 500 clinical training sessions annually, which strengthens its market position [2] Strategic Benefits - The collaboration is expected to provide a wider product selection for dental professionals and patients, enhancing the overall customer experience [4] - ZimVie's premium implants are designed for precision, aesthetics, and durability, aligning with the company's commitment to innovation and global expansion [4]
ZimVie Announces Definitive Agreement to be Acquired by ARCHIMED for $19.00 Per Share in Cash
GlobeNewswire News Room· 2025-07-21 12:00
PALM BEACH GARDENS, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (“ZimVie”) (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced their entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED (“ARCHIMED”), an investment firm focused exclusively on healthcare industries. Under the terms of the merger agreement, ZimVie stockholders will receive $19.00 in cash for each share of ZimVie common stock outstanding at the cl ...
Why Dentsply International (XRAY) is a Top Momentum Stock for the Long-Term
ZACKS· 2025-07-09 14:50
Company Overview - DENTSPLY SIRONA Inc. is a global leader in the design, development, manufacture, and marketing of dental consumables, dental laboratory products, dental specialty products, and consumable medical device products [11] - The company also provides dental technology products, including dental implants, scanning equipment, treatment software, and orthodontic appliances, as well as dental equipment such as treatment centers and imaging equipment [11] Investment Rating - DENTSPLY SIRONA Inc. has a Zacks Rank of 2 (Buy) and a VGM Score of A, indicating strong potential for investment [12] - The company has a Momentum Style Score of B, with shares increasing by 0.7% over the past four weeks [12] Earnings Estimates - Three analysts have revised their earnings estimates higher for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.03 to $1.90 per share [12] - DENTSPLY SIRONA Inc. has an average earnings surprise of +2.7%, suggesting positive performance relative to expectations [12] Conclusion - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, DENTSPLY SIRONA Inc. is recommended for investors' consideration [13]
Envista Announces Participation in Stifel 2025 Jaws & Paws Conference
Prnewswire· 2025-05-22 20:15
BREA, Calif., May 22, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in the Stifel 2025 Jaws & Paws Conference. The fireside chat will take place on Wednesday, May 28, 2025, from 1:50 – 2:20 pm ET.A live audio webcast of the event, along with an archived replay, will be available in the Investors section of the Envista website at https://investors.envistaco.com/. ABOUT ENVISTA HOLDINGS CORPORATIONEnvista is a global family of more ...
ZimVie to Participate in the Stifel 2025 Jaws & Paws Conference
Globenewswire· 2025-05-14 20:05
PALM BEACH GARDENS, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced management will participate in the upcoming Stifel 2025 Jaws & Paws Conference. Management will be presenting on Wednesday, May 28, 2025 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time. A live webcast of the event, as well as an archived recording will be available on ZimVie’s investor website at investor.zimvie.com. About ZimVieZimVie is a global lif ...
ZimVie Reports First Quarter 2025 Financial Results
Globenewswire· 2025-05-08 20:05
Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today reported financ ...
Henry Schein(HSIC) - 2025 Q1 - Earnings Call Transcript
2025-05-05 13:02
Henry Schein (HSIC) Q1 2025 Earnings Call May 05, 2025 08:00 AM ET Company Participants Graham Stanley - VP of Investor Relations & Strategic Finance Project OfficerStanley Bergman - Chairman and CEORonald South - Senior VP & CFOJonathan Block - Managing DirectorMichael Petusky - Managing DirectorJohn Stansel - VP - Equity Research Conference Call Participants Jason Bednar - Senior Research AnalystJeffrey Johnson - Senior Research AnalystElizabeth Anderson - Senior Managing Director & Research AnalystAllen ...